DEWNZAR HOWARD: Open Payments
NPI 1912016759 · DYER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$663 in 28 payments from 10 companies in 2025. Trend: 2023 $66 · 2024 $239 · 2025 $663
Food & beverage: $552Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $212 |
| Vanda Pharmaceuticals Inc. | 5 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Lundbeck LLC | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Noven Therapeutics, LLC | 2 | $37 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: FANAPT, REXULTI, COBENFY, UZEDY, Auvelity, ABILIFY MAINTENA, CAPLYTA, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
